Regeneron Pharmaceuticals REGN Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Regeneron Pharmaceuticals’s 10-K, filed February 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's operating lease liabilities (total)?
- Regeneron Pharmaceuticals (REGN) reported operating lease liabilities (total) of $266.8M in Q4 2025.
- What is the long-term trend for Regeneron Pharmaceuticals's operating lease liabilities (total)?
- Over 2 years (2023 to 2025), Regeneron Pharmaceuticals's operating lease liabilities (total) has grown at a 74.4% compound annual growth rate (CAGR), from $87.7M to $266.8M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.